AzTrials
AzTrials

Coronary StenosisVIPNCT03606330

Systemic, Pancoronary and Local Coronary Vulnerability

An observational study of Coronary Stenosis and Acute Coronary Syndrome, run by Cardio Med Medical Center at 1 site in Romania.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The aim of the VIP study is to investigate the impact of vulnerability markers (inflammatory serum biomarkers for systemic vulnerability, coronary shear stress and vulnerability mapping for pancoronary vulnerability, and imaging-based plaque features for systemic vulnerability) on the rate of major adverse… Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Cardiac imaging tests and Venous blood sample collection
How many people
100 participants
Where
1 siteRomania
Study dates
22 Oct 2018to 1 Mar 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: 100 patients with present ST and non-ST segment elevation myocardial infarction at 30 days prior to study enrollment, who underwent emergency revascularization of the culprit lesion.

Who may be able to join

  • Patients aged over 18 years old that have signed the written informed consent;
  • Patients with ST and non-ST segment elevation myocardial infarction (as stated in the Third Universal Definition of Myocardial Infarction) at 30 days prior to randomization;

Who cannot join

  • unwillingness or incapacity to provide informed consent (and if consent of legal guardian or family is not available);
  • acute myocardial infarction at the moment of randomization (as these patients are referred to the hospital for emergency invasive coronary angiography and revascularization)
  • conditions that present an estimated life expectancy of under 5 years;
  • acute renal failure or terminal stage chronic kidney disease;
  • pregnancy or lactation and women of reproductive age who are not using any contraceptive method;
  • allergy and history of allergic reactions to iodine contrast media;
  • active malignancy or malignancy within the last 1 year prior to enrollment;
  • patients who, in the opinion of the investigators are not compliant and will not present for study visits.

Trial locations and contacts

1 site in 1 country.

Romania1 site
  • Cardio Med

    Târgu Mureş, Mureș County

Other trials in Romania

About this study

Official title: Systemic, Pancoronary and Local Plaque Vulnerability for Image-based Prediction of Acute Coronary Syndromes - the VIP Study

  • The aim of the VIP study is to investigate the impact of vulnerability markers (inflammatory serum biomarkers for systemic vulnerability, coronary shear stress and vulnerability mapping for pancoronary vulnerability, and imaging-based plaque features for systemic vulnerability) on the rate of major adverse cardiovascular events caused by progression of the non-culprit lesion in patients with acute ST or non-ST segment elevation myocardial infarction who undergo revascularization of the culprit lesion during the acute event. Furthermore, the study will evaluate the rate of progression of non-culprit lesions towards a higher degree of vulnerability, based on coronary computed tomography angiographic assessment at 1 year after enrollment.
Read the detailed description

The project is a prospective, cohort, mono-centric study which will be carried out in the Center of Advanced Research in Multimodal Cardiac Imaging Cardiomed.

The project will include 100 subjects who present ST and non-ST segment elevation myocardial infarction at 30 days prior to study enrollment, who underwent emergency revascularization of the culprit lesion. Samples for systemic serum biomarkers for myocardial injury, myocardial strain and enhanced systemic inflammation will be collected at the moment of the acute event. All patients will undergo coronary CT angiography, cardiac perfusion CT and intracoronary imaging procedures (Intravascular ultrasound - IVUS; Optical Coherence Tomography - OCT) at the moment of enrollment in the study, for complex assessment of non-culprit coronary lesions. The endothelial coronary shear stress will be calculated with imaging post-processing techniques on the CT data acquired at baseline, by using computational fluid dynamics.

The study will be conducted over a period of 3 years, in which patients will be examined at baseline, and during several follow-up visits. At the one-year follow-up, the study subjects will undergo CT coronary angiography for re-evaluation of the non-culprit lesions, in the prospects of analyzing the rate of plaque progression towards a higher degree of vulnerability. At the end of the 3-year period, patients will be assessed about the occurrence of major adverse cardiovascular events and the rate or revascularization for non-culprit lesions.

Study objectives:

Primary: to investigate the association between systemic, pancoronary and local vulnerability features of coronary plaques and the risk for major adverse cardiac events - MACE (all-cause mortality, cardiovascular death, myocardial infarction, repeated revascularization, repeated hospitalizations for cardiovascular related incidents, cerebrovascular events) during a 3-year follow-up.

Secondary: to assess the rate of progression for the non-culprit lesions towards a higher degree of vulnerability, as evaluated via coronary CT angiography at 1 year after enrollment, in relation to systemic, pancoronary and local vulnerability features at baseline.

To identify the type of vulnerability (systemic, pancoronary or local) with the highest impact on plaque progression and future MACE

Study Timeline:

Baseline (day 0)

  • Obtain and document consent from participant on study consent form.
  • Verify inclusion/exclusion criteria.
  • Obtain demographic information, medical history, medication history, alcohol and tobacco use history.
  • Record results of physical examinations and 12-lead ECG.
  • Collect blood specimens.
  • Imaging procedures: transthoracic 2-D echocardiography, 128-multisclice CT angiography, cardiac perfusion CT, IVUS, OCT

Visit 1 (month 1)

  • Record results of physical examinations, 12-lead ECG and medical history.
  • Imaging procedures: transthoracic 2-D echocardiography

Visit 2 (month 3)

  • Telephone follow-up

Visit 3 (month 6)

  • Record results of physical examinations, 12-lead ECG and medical history.
  • Imaging procedures: transthoracic 2-D echocardiography

Visit 4 (month 12)

  • Record results of physical examinations, 12-lead ECG and medical history.
  • Imaging procedures: transthoracic 2-D echocardiography, 128-multislice CT coronary angiography for evaluation of non-culprit lesion
  • End-point evaluation

Visit 5 (month 15)

  • Telephone follow-up

Visit 6 (month 18)

  • Telephone follow-up

Visit 7 (month 24)

  • Record results of physical examinations, 12-lead ECG and medical history.
  • Imaging procedures: transthoracic 2-D echocardiography.
  • End-point evaluation

Visit 8 (month 30)

  • Telephone follow-up

Final study visit (month 36)

  • Record results of physical examinations, 12-lead ECG and medical history.
  • Imaging procedures: transthoracic 2-D echocardiography
  • End-point evaluation.

Study procedures:

  • Clinical examination, medical history
  • 12-lead ECG
  • 2D transthoracic echocardiography with measurement of: cardiac diameters, volumes, valvular function and regurgitation, pressure gradients, pericardial fat thickness, pericardial effusion, left ventricular global and regional function and ejection fraction.
  • 128-multislice CT coronary angiography with the evaluation of: epicardial fat volume, plaque burden, total and local calcium score, markers for lesion severity (degree of stenosis, lesion length, lumen area and diameter, minimum and maximum plaque thickness); morphological plaque characteristics (plaque related volumes, plaque burden, vascular indexes - remodeling and eccentricity index); plaque components evaluated via volumetric and planimetric units (necrotic core, fibrofatty tissue, fibrotic tissue, dense calcium); markers of plaque vulnerability (necrotic core, low attenuation plaque, spotty calcification, napkin ring sign, positive remodeling).
  • Shear stress evaluation of CT acquired images and computational fluid dynamics
  • Intracoronary imaging techniques: IVUS and OCT with evaluation of plaque characteristics.
  • Venous blood sample collection during the acute coronary event for evaluation of serum levels of hsCRP, IL-6, matrixmetalloproteases MMP9, Adhesion molecules (VCAM, ICAM), alfa tumour necrosis factor, hs-cTnI, NTproBNP

Data collection: In a dedicated database that includes all patient information, demographics, medical history, medication, therapeutic procedures, information derived from imaging techniques (echocardiography, CT angiography, CT imaging post-processing and shear stress evaluation).

Being tested
Cardiac imaging tests, Venous blood sample collection
Keywords
coronary artery disease, myocardial infarction, cardiac imaging techniques, major adverse cardiovascular events, vulnerable coronary plaques, serum biomarkers, coronary shear stress
Medical subject headings
Coronary Stenosis, Acute Coronary Syndrome, Plaque, Atherosclerotic, Coronary Artery Disease, Non-ST Elevated Myocardial Infarction, Myocardial Infarction

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cardiac imaging testsDiagnostic test

    • 2D transthoracic echocardiography
    • 128-multislice CT coronary angiography with the evaluation of: epicardial fat volume, plaque burden, total and local calcium score, markers for lesion severity; morphological plaque characteristics; plaque components evaluated via volumetric and planimetric units; markers of plaque vulnerability (necrotic core, low attenuation plaque, spotty calcification, napkin ring sign, positive remodeling).
    • Shear stress evaluation via computational fluid dynamics.
    • Intracoronary imaging techniques: IVUS and OCT.
  • Venous blood sample collectionDiagnostic test

    Venous blood sample collection during the acute coronary event for evaluation of serum levels of hsCRP, IL-6, matrixmetalloproteases MMP9, Adhesion molecules (VCAM, ICAM), alfa tumour necrosis factor, hs-cTnI, NTproBNP

Study groups in NCT03606330
Study groupRoleWhat they receive
VP-SG 01Study subjects that present MACE at the 36 months follow-up
Receives: Diagnostic Test: Cardiac imaging tests; Diagnostic Test: Venous blood sample collection
VP-SG 02Study subjects that do not present MACE at the 36 months follow-up
Receives: Diagnostic Test: Cardiac imaging tests; Diagnostic Test: Venous blood sample collection

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. MACE rate - Major adverse cardiovascular events

    Acute coronary syndromes (unstable angina, ST and non-ST elevation myocardial infarction), emergency revascularization of non-culprit lesions, repeated hospitalizations for cardiovascular reasons, acute cerebrovascular event.

    Measured: 36 months

Secondary outcomes (2)
  1. Severity progression of non-culprit coronary lesions

    Reevaluation of the non-culprit lesions via 128-multislice CT coronary angiography with analysis of the degree of stenosis caused by the non-culprit lesion.

    Measured: 12 months

  2. Progression rate of CT markers for coronary plaque vulnerability

    Reevaluation of the non-culprit lesions via 128-multislice CT coronary angiography with analysis of the number of CT markers for coronary plaque vulnerability (low attenuation plaque, spotty calcification, napkin ring sign, positive remodeling).

    Measured: 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Jul 2018
  2. Study start22 Oct 2018
  3. Primary completion22 Oct 2019
  4. Study completion1 Mar 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
100 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03606330
Sponsor's protocol ID
CM0118-PLI-3
Acronym
VIP
Status last verified
Dec 2019
First submitted
26 Jun 2018
Last updated
2 Aug 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: All IPD that underlie results in a publication will be available for interested parties.

Questions about this trial

What is this clinical trial studying?

An observational study of Coronary Stenosis and Acute Coronary Syndrome, run by Cardio Med Medical Center at 1 site in Romania.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 Aug 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Romania. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

MACE rate - Major adverse cardiovascular events (time frame: 36 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Aug 2022.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in